A 30-year-old man was studied who had hyperlipidemia of a hereditary nature which was at first thought to be refractory to changes in diet. It was subsequently shown that the lipemia was adequately controlled by diet. The patient had no defect in his ability to produce clearing-factor lipase (CFL) following heparin injection, his chylomicra were not refractory to CFL, and his plasma showed no more than ordinary inhibitory activity against CFL. Under dietary conditions which resulted in a high degree of lipemia, much of the CFL was rendered inactive by adsorption on the chylomicra. The results suggest that the role of CFL in patients with hyperlipidemia may be minor.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1927742 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Insulin Therapy for Acute Pancreatitis in a Patient With Lipase Maturation Factor 1 Mutation: A Case Report.
J Community Hosp Intern Med Perspect
January 2025
Department of Medicine, Division of General Internal Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Acute pancreatitis is a frequent cause of hospital admission, managed with intravenous (IV) fluids, analgesia, and oral feeding when tolerated. In patients with hypertriglyceridemia-induced pancreatitis, insulin and other therapies may be necessary for disease resolution. We present a case of a patient with severe acute pancreatitis and euglycemic diabetic ketoacidosis (DKA) with known lipase maturation factor 1 (LMF1) gene mutations, which can impact insulin efficacy on triglyceride metabolism through altered lipoprotein lipase activity, successfully treated with intravenous insulin.
View Article and Find Full Text PDFGenetic association of lipid-lowering drug target genes with pancreatic cancer: a Mendelian randomization study.
Sci Rep
January 2025
Division of Pancreatic Surgery, Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, China.
Previous studies have found that dyslipidemia is a risk factor for pancreatic cancer (PC), and that lipid-lowering drugs may reduce the risk of PC. However, it is not clear whether dyslipidemia causes PC. The Mendelian randomization (MR) study aimed to investigate the causal role of lipid traits in pancreatic cancer and to assess the potential impact of lipid-lowering drug targets on pancreatic cancer.
View Article and Find Full Text PDFSafety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Lancet Neurol
February 2025
Department of Neurology, International University of Health and Welfare, Narita, Japan.
Background: Evidence from preclinical studies suggests that IL-6 signalling has the potential to modulate immunopathogenic mechanisms upstream of autoantibody effector mechanisms in patients with generalised myasthenia gravis. We aimed to assess the safety and efficacy of satralizumab, a humanised monoclonal antibody targeting the IL-6 receptor, in patients with generalised myasthenia gravis.
Methods: LUMINESCE was a randomised, double-blind, placebo-controlled, multicentre, phase 3 study at 105 sites, including hospitals and clinics, globally.
Lipoprotein Lipase: Structure, Function, and Genetic Variation.
Genes (Basel)
January 2025
Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, 4288A-1151 Richmond Street North, London, ON N6A 5B7, Canada.
Biallelic rare pathogenic loss-of-function (LOF) variants in lipoprotein lipase () cause familial chylomicronemia syndrome (FCS). Heterozygosity for these same variants is associated with a highly variable plasma triglyceride (TG) phenotype ranging from normal to severe hypertriglyceridemia (HTG), with longitudinal variation in phenotype severity seen often in a given carrier. Here, we provide an updated overview of genetic variation in in the context of HTG, with a focus on disease-causing and/or disease-associated variants.
View Article and Find Full Text PDFEffects of Dietary Tea Polyphenols on the Growth, Antioxidant Status, Immune Function, and Intestinal Microbiota of Largemouth Bass ().
Animals (Basel)
January 2025
College of Marine Sciences, South China Agricultural University, Guangzhou 510642, China.
This research aimed to explore the impact of tea polyphenol (TP) supplementation on the development, antioxidant properties, immune responses, and gut wellness in largemouth bass (, LMB). Four diets with varying levels of TPs (0.00%, 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!